Biopharmaceutical benchmarks

Walsh, Gary

doi:10.1038/78720

Cited by 384 publications

(401 citation statements)

References 5 publications

Supporting

Mentioning

375

Contrasting

Unclassified

Order By: Relevance

“…Most of therapeutic proteins arrived to the market are produced in mammalian cells [61]. Mammalian cells have host-specific glycosylation of virus antigens, which is different from that in insect cells, plants and yeasts.…”

Section: Mammalian Cellsmentioning

confidence: 99%

Functional Virus-Like Particles Production Using Silkworm and Their Application in Life Science

Kato¹,

Deo²,

Park

et al. 2012

J Biotechnol Biomaterial

View full text Add to dashboard Cite

Virus-like particles (VLPs), which mimic the structure of authentic virus, are of significant importance owing to their wide ranging applications. VLPs have the potential to serve as candidate vaccine in addition to subunit vaccines and also serve as a nano-bioparticle scaffold for displaying complex foreign proteins. Here, we review different methods available to produce VLPs with various host expression systems including from microorganisms to mammalian cells and the current potential of silkworms as producers of these VLPs. Recently, silkworms have been used for efficient production of VLPs too in addition to mass production of recombinant proteins, which have contributed to molecular structural analysis, molecule-molecule interactions in biology and biotechnology.

show abstract

Section: Mammalian Cellsmentioning

confidence: 99%

Functional Virus-Like Particles Production Using Silkworm and Their Application in Life Science

Kato¹,

Deo²,

Park

et al. 2012

J Biotechnol Biomaterial

View full text Add to dashboard Cite

show abstract

“…The contribution of biopharmaceutical industries to general healthcare is rapidly increasing, with over 165 such industries having been approved globally since 1982 (Walsh 2006). Within the therapeutic applications of biopharmaceuticals, monoclonal antibodies (MAbs) are of growing interest (Burnouf 2011;Grillberger et al 2009;Mori et al 2007), and are generally administered as active proteins in large amounts and at high protein concentrations, unlike other aqueous proteinaceous biopharmaceuticals such as cytokines.…”

Section: Introductionmentioning

confidence: 99%

Fucose content of monoclonal antibodies can be controlled by culture medium osmolality for high antibody-dependent cellular cytotoxicity

et al. 2011

View full text Add to dashboard Cite

Antibody-dependent cellular cytotoxicity (ADCC) is dependent on the fucose content of oligosaccharides bound to monoclonal antibodies (MAbs). As MAbs with a low fucose content exhibit high ADCC activity, it is important to control the defucosylation levels (deFuc%) of MAbs and to analyze the factors that affect deFuc%. In this study, we observed that the deFuc% was inversely related to culture medium osmolality for MAbs produced in the rat hybridoma cell line YB2/0, with r 2 values as high as 0.92. Moreover, deFuc% exhibited the same correlation irrespective of the type of compound used for regulating osmolality (NaCl, KCl, fucose, fructose, creatine, or mannitol) at a culture scale ranging from 1 to 400 L. We succeeded in controlling MAb deFuc% by maintaining a constant medium osmolality in both perfusion and fed-batch cultures. In agreement with these observations, reverse transcription PCR analyses revealed decreased transcription of genes involved in glycolysis, GDP-fucose supply, and fucose transfer under hypoosmotic conditions.

show abstract

“…One such technological platform is based on the use of mammalian cell lines for the production of complex biomolecular products. In 2006 it was reported that over 165 new biopharmaceutical entities received FDA approval (Walsh 2006). Mammalian cell lines command an effective monopoly towards production of complex therapeutic proteins that require post-translational modifications (Walsh 2006;Walsh and Jefferis 2006).…”

Section: Introductionmentioning

confidence: 99%

“…In 2006 it was reported that over 165 new biopharmaceutical entities received FDA approval (Walsh 2006). Mammalian cell lines command an effective monopoly towards production of complex therapeutic proteins that require post-translational modifications (Walsh 2006;Walsh and Jefferis 2006). This unique advantage outweighs the costs associated with mammalian cell culture, which are far greater in terms of development time and manufacturing when compared to bacterial culture.…”

Section: Introductionmentioning

confidence: 99%

Using cell engineering and omic tools for the improvement of cell culture processes

et al. 2007

View full text Add to dashboard Cite

Significant strides have been made in mammalian cell based biopharmaceutical process and cell line development over the past years. With several established mammalian host cell lines and expression systems, optimization of selection systems to reduce development times and improvement of glycosylation patterns are only some of the advances being made to improve cell culture processes. In this article, the advances pertaining to cell line development and cell engineering strategies are discussed. An overview of the cell engineering strategies to enhance cellular characteristics by genetic manipulation are illustrated, focusing on the use of genomics and proteomics tools and their application in such endeavors. Included in this review are some of the early studies using the 'omic' technique to understand cellular mechanisms of product synthesis and secretion, apoptosis, cell proliferation and the influence of the physicochemical environment. The article highlights the significance of integrating genomics and proteomics data with the vast amounts of bioprocess data for improved analysis of the biological pathways involved. Further improvements of the techniques and methodologies used are needed but ultimately, the new cell engineering strategies should provide great insight into the regulatory networks within the cell in a bioprocess environment and how to manipulate them to increase overall productivity.

show abstract

Biopharmaceutical benchmarks

Cited by 384 publications

References 5 publications

Functional Virus-Like Particles Production Using Silkworm and Their Application in Life Science

Functional Virus-Like Particles Production Using Silkworm and Their Application in Life Science

Fucose content of monoclonal antibodies can be controlled by culture medium osmolality for high antibody-dependent cellular cytotoxicity

Using cell engineering and omic tools for the improvement of cell culture processes

Contact Info

Product

Resources

About